BOSTON, April 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that the scientific team who worked on the clinical development programs for NUZYRA™ (omadacycline) and SEYSARA™ (sarecycline) were awarded the American Chemical Society’s (ACS) 2019 Heroes of Chemistry Award.
NUZYRA and SEYSARA are the first two medications in a new class of tetracycline antibiotics. NUZYRA, for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI), and SEYSARA, for the treatment of moderate to severe acne in patients 9 years of age and older, were both approved by the U.S. Food and Drug Administration in October 2018.
“We are honored that the American Chemical Society has recognized our team of scientists and their contributions to developing two distinct modernized tetracycline molecules,” said Evan Loh, M.D., President, Chief Operating Officer, and Chief Medical Officer, Paratek. “Their important work has given clinicians access to two new, effective, well-tolerated therapies, NUZYRA for life-threatening community-acquired infections and SEYSARA for moderate to severe acne.”
The Heroes of Chemistry program recognizes scientists whose innovative work in chemistry, chemical engineering and clinical development led to the commercialization of these products for the benefit of patients. The 2019 Heroes of Chemistry awards ceremony will take place Sunday, August 25 during the Society’s 257th National Meeting & Exposition in San Diego, CA.
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The company’s lead commercial product, NUZYRA (omadacycline), which has launched and is available in the U.S., is a once-daily oral and intravenous antibiotic for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek is also studying NUZYRA for the treatment of urinary tract infections (UTI).
